LEOBETA-N

This brand name is authorized in Nigeria.

Active ingredients

The drug LEOBETA-N contains a combination of these active pharmaceutical ingredients (APIs):

1	Betamethasone UNII 7BK02SCL3W - BETAMETHASONE SODIUM PHOSPHATE
	Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties.
	Read more about Betamethasone
2	Neomycin UNII 057Y626693 - NEOMYCIN SULFATE
	Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code.
	Read more about Neomycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-6930	Ear/eye drops	LEOBETA-N EYE/EAR DROPS SOL_DROPS 0.1%; 0.5% 7.5ML	73 RNW-PP-241361 LEOBETA-N EYE/EAR DROPS BETAMETHASONE SODIUM 0.1%W/V , NEOMYCIN SULPHATE BP 0.5%W/V BETAMETHASONE SODIUM PHOSPAHTE BP 0.1%W/V, NEOMYCIN SULPHATE BP 0.5%W/V , THIOMERSAL BP 0.005%W/V (AS PRESERVATIVE) List of excipients 1. Disodium EDTA 2. Sodium Metabisulphite 3. Disodium Hydrogen Phosphate 4. Sodium Dihydrogen Phosphate 5. Polyethylene Glycol (P.E.G.) 400 6. Thiomersal 7. Sodium Hydroxide 8. Water for Injection B4-6930 Drugs Imported Products 7.5ML POM 1 11/30/2021 ANLEOSON PHARMACEUTICAL LTD, CHIEF MARCEL ANYANSI AVENUE, OGIDI IDEMILI NORTH ONITSHA ANAMBRA 8034144316 anleosoncoy@gmail.com ALPA LABOURATORIES LTD, 33/2,PIGDAMBER A.B,ROAD-453 446 DIST. INDORE-(M.P)INDIA, India	23/02/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S03CA06	Betamethasone and antiinfectives	S Sensory organs → S03 Ophthalmological and otological preparations → S03C Corticosteroids and antiinfectives in combination → S03CA Corticosteroids and antiinfectives in combination
Discover more medicines within S03CA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-6930